86 results
Keyword ipilimumab Remove keyword
-
List item
Press release: New treatment option recommended for patients with advanced melanoma
CHMP, Last updated: 22/05/2015other comparing Keytruda with ipilimumab, another melanoma treatment … had not previously received ipilimumab and in patients who had previously … who had previously received ipilimumab. The Committee also looked … -
List item
Press release: European Medicines Agency recommends approval of Tafinlar for the treatment of metastatic melanoma
CHMP, Last updated: 28/06/2013them, the monoclonal antibody ipilimumab, targets a molecule found … them, the monoclonal antibody ipilimumab, targets a molecule found … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020
CHMP, Last updated: 28/02/2020ipilimumab) in the treatment of metastatic … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018
CHMP, Last updated: 16/11/2018ipilimumab) in combination to treat … -
List item
Press release: European Medicines Agency recommends approval of Mekinist for the treatment of melanoma
CHMP, Last updated: 25/04/2014including a monoclonal antibody (ipilimumab) that targets a molecule … a monoclonal antibody (ipilimumab) that targets a molecule … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018
CHMP, Last updated: 21/09/2018ipilimumab) have requested re-examination … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018
CHMP, Last updated: 27/07/2018ipilimumab) in combination to treat … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018
CHMP, Last updated: 27/04/2018Name of medicine Yervoy INN ipilimumab Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2017
CHMP, Last updated: 15/12/2017Name of medicine Yervoy INN ipilimumab Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2013
CHMP, Last updated: 20/09/2013Yervoy INN ipilimumab Marketing-authorisation holder … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2011
CHMP, Last updated: 20/05/2011ipilimumab), from Bristol-Myers Squibb … 210 days. • Yervoy (ipilimumab), from Bristol-Myers Squibb … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020
CHMP, Last updated: 18/09/2020Yervoy INN ipilimumab Marketing-authorisation applicant … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 October 2020
Virtual meeting, from 26/10/2020 to 29/10/2020, Last updated: 08/01/2021durvalumab – IMFINZI (CAP); ipilimumab – YERVOY (CAP); pembrolizumab … -
List item
Committee for Medicinal Products for Human Use (CHMP): 9-12 November 2020
Virtual meeting, from 09/11/2020 to 12/11/2020, Last updated: 07/01/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 July 2020
European Medicines Agency, Amsterdam, the Netherlands, from 06/07/2020 to 09/07/2020, Last updated: 10/12/2020 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2021 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 08/02/2021 to 11/02/2021, Last updated: 08/02/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 23-26 November 2020
Virtual meeting, from 23/11/2020 to 26/11/2020, Last updated: 27/11/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-29 January 2021 (updated)
Virtual meeting, from 25/01/2021 to 29/01/2021, Last updated: 29/01/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 October 2020
Virtual meeting, from 12/10/2020 to 15/10/2020, Last updated: 16/10/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 14-17 September 2020
Virtual meeting, from 14/09/2020 to 17/09/2020, Last updated: 14/09/2020 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 14-17 May 2018
European Medicines Agency, London, UK, from 14/05/2018 to 17/05/2018, Last updated: 14/05/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 February 2018
European Medicines Agency, London, UK, from 19/02/2018 to 22/02/2018, Last updated: 06/04/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 31 August-3 September 2020
Virtual meeting, from 31/08/2020 to 03/09/2020, Last updated: 27/02/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 23-26 April 2018
European Medicines Agency, London, UK, from 23/04/2018 to 26/04/2018, Last updated: 08/06/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 11-14 June 2018
European Medicines Agency, London, UK, from 11/06/2018 to 14/06/2018, Last updated: 10/08/2018